AIM: The study was to retrospectively analyze survival outcomes of surgery combined with chemotherapy in primary @entity4153 of esophagus. METHODS: From January 2000 to December 2009, all @entity1 with @entity418 and underwent esophagectomy were selected from the Department of Thoracic Surgery, Henan Cancer Hospital, China. They were performed trans--left thoracic incision esophagectomy. For @entity5 located in the upper third thoracic esophagus, trans--right thoracic incision and abdomen incision esophagectomy was selected. We chose EP regimen for chemotherapy. Results: The percentage of pure @entity4153 (57 cases) in all @entity1 underwent esophagectomy was 1.1%. The median survival time was 45 months. In stage I, II, III, the survival rate was 25%, 5.9%, 4.3% respectively. In the subgroup analysis, overall median survival time of surgery was 23.2 months while the time of combined surgery and chemotherapy was 60.7months (P   0.01). For stage I @entity1 , combined therapy was associated with a significant longer median survival time (81.9 months) than surgery alone (22.3months). (P   0.01). CONCLUSION: Systemic chemotherapy of @entity900 --based regimens should be considered as important treatment options to improve survival outcome   even early small cell esophageal cancer.

Combined chemotherapy and surgery in primary XXXX of the esophagus.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['small cell carcinoma', 'esophagus small cell carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal carcinoma']
@entity4153 :: (MESH:D018288,Disease) :: ['small cell carcinoma']
